Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B - Trial NCT06154278
Access comprehensive clinical trial information for NCT06154278 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Maryland, Baltimore and is currently Not yet recruiting. The study focuses on Chronic Hepatitis B. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Maryland, Baltimore
Timeline & Enrollment
Phase 2
Dec 01, 2023
Jul 01, 2026
Primary Outcome
Intrahepatic concentration of Imdusiran (AB-729)
Summary
The goal of this clinical trial is to learn about the action of Imdusiran (AB-729) in the
 liver of people with chronic hepatitis B. The main questions it aims to answer are:
 
 - how well is it working in the liver
 
 - how does Imdusiran affect the hepatitis B virus
 
 Participants will receive injections of Imdusiran, one injection every 8 weeks, for a total
 of 4 doses. They will also undergo 2 liver biopsies: one with the first dose of Imdusiran,
 and the second 8 weeks after the last dose of Imdusiran.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06154278
Non-Device Trial